Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 11,958 Shares of Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 11,958 shares of the business's stock in a transaction on Tuesday, December 24th. The shares were acquired at an average cost of $14.12 per share, for a total transaction of $168,846.96. Following the transaction, the director now directly owns 14,704,239 shares in the company, valued at approximately $207,623,854.68. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The shares were acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Price Performance

Shares of ZYME stock remained flat at $14.50 on Friday. The company had a trading volume of 461,479 shares, compared to its average volume of 609,735. The firm has a market capitalization of $998.73 million, a price-to-earnings ratio of -9.67 and a beta of 1.12. The firm has a 50-day moving average of $14.25 and a 200 day moving average of $12.00. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The company had revenue of $16.00 million during the quarter, compared to the consensus estimate of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.41) earnings per share. Equities analysts forecast that Zymeworks Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZYME has been the topic of several recent research reports. Citigroup increased their target price on Zymeworks from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Monday, November 4th. Leerink Partners raised Zymeworks from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $10.00 to $25.00 in a research report on Thursday, November 7th. Stifel Nicolaus boosted their target price on shares of Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, October 28th. HC Wainwright restated a "neutral" rating and issued a $12.00 target price on shares of Zymeworks in a research note on Friday, November 22nd. Finally, Wells Fargo & Company upped their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.17.

Hedge Funds Weigh In On Zymeworks

A number of institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC grew its position in Zymeworks by 55.2% during the second quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company's stock worth $14,192,000 after buying an additional 592,904 shares during the period. Rubric Capital Management LP grew its stake in Zymeworks by 12.7% in the 2nd quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company's stock worth $33,336,000 after acquiring an additional 441,947 shares during the period. Dimensional Fund Advisors LP increased its stake in Zymeworks by 127.5% in the second quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company's stock valued at $6,090,000 after purchasing an additional 401,068 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Zymeworks during the 3rd quarter worth about $4,156,000. Finally, Point72 Asset Management L.P. purchased a new position in Zymeworks during the second quarter worth approximately $1,683,000. 92.89% of the stock is owned by institutional investors and hedge funds.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.